All In MedTech

Device Trial Radar · NCT04241718

A Feasibility Study on Ultrafiltration and Blood Volume Measurements

Last checked: Nov 20, 2026Latest source record: Nov 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

6

Actual

Start

Dec 19, 2019

Primary completion

Dec 27, 2022

Study completion Dec 27, 2022

Sponsor

Lead sponsor
Nuwellis, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Daxor Corporation
First posted
Jan 27, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this feasibility study is to characterize the performance of the Aquadex FlexFlow® System with the hematocrit (HCT) feature in conjunction with Daxor's blood volume analyzer (BVA-100). The study will monitor blood volume changes during ultrafiltration (UF) therapy as a potential means to guide the removal of fluid in subjects hospitalized with acute decompensated heart failure (ADHF).

Conditions

  • Acute Decompensated Heart Failure
  • Fluid Overload

Interventions

  • Aquadex FlexFlow System and BVA-100Device

    Aquapheresis therapy with Aquadex FlexFlow System and Blood Volume Measurement with BVA-100

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1. Evaluate changes in blood volume as measured by BVA from before initiation until completion of extracorporeal fluid removal by ultrafiltrationTime frame: Through study procedure completion, average of 2 weeks
  2. 2. Evaluate if changes in blood volume, as measured by BVA, correlate with changes in HCT as measured by the device embedded in the Aquadex FlexFlow System ultrafiltration deviceTime frame: Through study procedure completion, average of 2 weeks
  3. 3. Evaluate the temporal relationship between changes in blood volume, as measured by BVA , and changes in clinical signs and symptoms of fluid overloadTime frame: Through study procedure completion, average of 2 weeks

5 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Midwest Cardiovascular Institute

    Naperville, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.